New Jersey A2645 requires physicians to offer testing for dihydropyrimidine dehydrogenase deficiency before chemotherapy.

New Jersey A2645 mandates that physicians offer testing for dihydropyrimidine dehydrogenase deficiency, a disorder that impairs the body's ability to break down chemotherapy drugs, potentially leading to harmful reactions. The bill also requires health insurance plans to cover the cost of one annual test for this deficiency and any related prescription drug treatments, provided the plans offer prescription drug benefits. This applies to individual, group, and health maintenance organization contracts, as well as small employer health benefits plans.

New Jersey A2645 requires physicians to offer testing for dihydropyrimidine dehydrogenase deficiency before chemotherapy.

New Jersey A2645 mandates that physicians offer testing for dihydropyrimidine dehydrogenase deficiency, a disorder that impairs the body's ability to break down chemotherapy drugs, potentially leading to harmful reactions. The bill also requires health insurance plans to cover the cost of one annual test for this deficiency and any related prescription drug treatments, provided the plans offer prescription drug benefits. This applies to individual, group, and health maintenance organization contracts, as well as small employer health benefits plans.